EGFR and colorectal carcinoma: The above phenomena provide a mechanistic rationale for exploring the combined use of anti-EGFR and vitamin C therapies to directly target both the essential resources themselves (EGF) and the pivotal player involved in obtaining resources (glucose transporter) for CRC.